---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-049888"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:50:55.469056+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evommune announces $125M private placement of 4.5M shares at $27.88/share

## Summary
- Gross proceeds ~$125M from sale of 4,494,279 shares at $27.88 per share to institutional investors.
- Investors include new and existing mutual funds and dedicated healthcare funds.
- Net proceeds to advance clinical development programs and for general corporate purposes.
- Transaction expected to close on or about February 17, 2026, subject to customary conditions.
- Registration rights agreement filed; resale registration statement to be filed within 60 days.

## SEC filing metadata
- accession: 0001193125-26-049888
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526049888/0001193125-26-049888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526049888/evmn-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-049888
- JSON: https://secwatch.observer/filing/0001193125-26-049888.json
- Plain text: https://secwatch.observer/filing/0001193125-26-049888.txt

## Key facts
- Material Agreements
  Evommune, Inc. entered into Registration Rights Agreement with certain investors (effective 2026-02-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Effective: 2026-02-12
  source text: In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated February 12, 2026 (the “Registration Rights Agreement”), with the Investors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2044725/000119312526049888/0001193125-26-049888-index.htm
- Material Agreements
  Evommune, Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $125 million (effective 2026-02-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: approximately $125 million
  - Effective: 2026-02-12
  source text: On February 12, 2026, Evommune, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of 4,494,279 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). Each Share was offered and sold at a purchase price of $27.88 before deducting underwriting discounts and commissions. The Private Placement is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions. The Company estimates that the gross proceeds to the Company from the Private Placement will be approximately $125 million, before deducting any transaction-related expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2044725/000119312526049888/0001193125-26-049888-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.